Product nameAnti-TRAF2 antibody [EPR7064]
See all TRAF2 primary antibodies
DescriptionRabbit monoclonal [EPR7064] to TRAF2
Tested applicationsSuitable for: WB, IHC-P, ICC/IF, IP, Flow Cytmore details
Species reactivityReacts with: Human
Recombinant fragment corresponding to Human TRAF2.
- Purchase matching WB positive control:Human TRAF2 full length protein
- Molt-4, 293T, Raji and HeLa whole cell lysate (ab150035); Human kidney tissue; HeLa cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab167163 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 55 kDa.|
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|ICC/IF||1/100 - 1/250.|
|IP||1/10 - 1/100.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionRegulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'-linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin-protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain.
PathwayProtein modification; protein ubiquitination.
Sequence similaritiesBelongs to the TNF receptor-associated factor family. A subfamily.
Contains 1 MATH domain.
Contains 1 RING-type zinc finger.
Contains 2 TRAF-type zinc fingers.
DomainThe coiled coil domain mediates homo- and hetero-oligomerization.
The MATH/TRAF domain binds to receptor cytoplasmic domains.
The RING-type zinc finger domain is essential for E3 ubiquitin-protein ligase activity. It is not essential for the stabilization of BIRC2, or for the ubiquitination of RIPK1 in response to TNFR1 signaling.
modificationsPhosphorylated at several serine residues within the first 128 amino acid residues. Phosphorylated at Thr-117 in response to signaling via TNF and TNFRSF1A. Phosphorylation at Thr-117 is required for 'Lys-63'-linked polyubiquitination, but not for 'Lys-48'-linked polyubiquitination. Phosphorylation at Thr-117 is important for interaction with IKKA and IKKB, activation of IKK and subsequent activation of NF-kappa-B.
Undergoes both 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination. Polyubiquitinated via 'Lys-63'-linked ubiquitin in response to TNF signaling; this requires prior phosphorylation at Thr-117. 'Lys-63'-linked polyubiquitination promotes TRAF2-mediated activation of NF-kappa-B. Can be polyubiquitinated at several Lys residues via 'Lys-48'-linked ubiquitin chains in response to TNF signaling, leading to proteasomal degradation. Autoubiquitinated, leading to its subsequent proteasomal degradation. Polyubiquitinated by BIRC2 and SIAH2, leading to its subsequent proteasomal degradation. Deubiquitinated by CYLD, a protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains.
- Information by UniProt
- E3 ubiquitin-protein ligase TRAF2 antibody
- MGC:45012 antibody
- OTTHUMP00000022625 antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: TRAF2 knockout HAP1 cell lysate (20 µg)
Lane 3: Human skeletal muscle tissue lysate (20 µg)
Lane 4: U20S cell lysate (20 µg)
Lanes 1 and 2: Merged signal (red and green). Green - ab167163 observed at 58 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab167163 was shown to recognize TRAF2 when TRAF2 knockout samples were used, along with additional cross-reactive bands. Wild-type and TRAF2 knockout samples were subjected to SDS-PAGE. ab167163 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-TRAF2 antibody [EPR7064] (ab167163) at 1/1000 dilution
Lane 1 : Molt-4 cell lysate
Lane 2 : 293T cell lysate
Lane 3 : Raji cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labeled goat anti-rabbit at 1/2000 dilution
Predicted band size: 55 kDa
Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling TRAF2 with ab167163 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Immunofluorescent analysis of HeLa cells labeling TRAF2 with ab167163 at 1/100 dilution.
ab167163 has not yet been referenced specifically in any publications.